The purpose of this study is to compare the efficacy and tolerability of ziprasidone versus
olanzapine in the treatment of acute mania. An open label extension will further evaluate the
efficacy, safety, and tolerability of ziprasidone compared with olanzapine. Study recruitment
was stopped due to difficulty in enrolling the targeted number of patients on July 30, 2007.
Subjects that were enrolled at the time completed the study as per protocol. There were no
safety concerns involved in the decision to stop enrollment. The Last Subject Last Visit was
January 10, 2008.
Phase:
Phase 4
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.